MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 3, 2008; DOI: 10.1124/mol.107.043422


0026-895X/08/7403-562-573$20.00
Mol Pharmacol 74:562-573, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.043422v1
74/3/562    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stanasila, L.
Right arrow Articles by Cotecchia, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanasila, L.
Right arrow Articles by Cotecchia, S.

Different Internalization Properties of the {alpha}1a- and {alpha}1b-Adrenergic Receptor Subtypes: The Potential Role of Receptor Interaction with β-Arrestins and AP50Formula

Laura Stanasila, Liliane Abuin, Julien Dey, and Susanna Cotecchia

Département de Pharmacologie et Toxicologie, Faculté de Biologie et de Médecine, Lausanne, Switzerland

The internalization properties of the {alpha}1a- and {alpha}1b-adrenergic receptors (ARs) subtypes transiently expressed in human embryonic kidney (HEK) 293 cells were compared using biotinylation experiments and confocal microscopy. Whereas the {alpha}1b-AR displayed robust agonist-induced endocytosis, the {alpha}1a-AR did not. Constitutive internalization of the {alpha}1a-AR was negligible, whereas the {alpha}1b-AR displayed significant constitutive internalization and recycling. We investigated the interaction of the {alpha}1-AR subtypes with β-arrestins 1 and 2 as well as with the AP50 subunit of the clathrin adaptor complex AP2. The results from both coimmunoprecipitation experiments and β-arrestin translocation assays indicated that the agonistinduced interaction of the {alpha}1a-AR with β-arrestins was much weaker than that of the {alpha}1b-AR. In addition, the {alpha}1a-AR did not bind AP50. The {alpha}1b-AR mutant M8, lacking the main phosphorylation sites in the receptor C tail, was unable to undergo endocytosis and was profoundly impaired in binding β-arrestins despite its binding to AP50. In contrast, the {alpha}1b-AR mutant {Delta}R8, lacking AP50 binding, bound β-arrestins efficiently, and displayed delayed endocytosis. RNA interference showed that β-arrestin 2 plays a prominent role in {alpha}1b-AR endocytosis. The findings of this study demonstrate differences in internalization between the {alpha}1a- and {alpha}1b-AR and provide evidence that the lack of significant endocytosis of the {alpha}1a-AR is linked to its poor interaction with β-arrestins as well as with AP50. We also provide evidence that the integrity of the phosphorylation sites in the C tail of the {alpha}1b-AR is important for receptor/β-arrestin interaction and that this interaction is the main event triggering receptor internalization.


Received November 10, 2007; accepted June 2, 2008

Address correspondence to: Prof. Susanna Cotecchia, Département de Pharmacologie et de Toxicologie, Rue du Bugnon 27, CH-1005 Lausanne. E-mail: susanna.cotecchia{at}unil.ch







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics